116 related articles for article (PubMed ID: 37844446)
21. EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Jo U; Park KH; Whang YM; Sung JS; Won NH; Park JK; Kim YH
Oncotarget; 2014 Mar; 5(5):1265-78. PubMed ID: 24658031
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
23. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
Yamaoka T; Ohba M; Arata S; Ohmori T
J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
[TBL] [Abstract][Full Text] [Related]
24. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
[TBL] [Abstract][Full Text] [Related]
26. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Wang W; Li Q; Yamada T; Matsumoto K; Matsumoto I; Oda M; Watanabe G; Kayano Y; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2009 Nov; 15(21):6630-8. PubMed ID: 19843665
[TBL] [Abstract][Full Text] [Related]
27. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
28. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
29. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
30. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
31. [The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):1-6. PubMed ID: 23327866
[TBL] [Abstract][Full Text] [Related]
32. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S; Takeuchi S; Nakagawa T; Yamada T
Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
[TBL] [Abstract][Full Text] [Related]
33. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
34. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.
Gusenbauer S; Vlaicu P; Ullrich A
Oncogene; 2013 Aug; 32(33):3846-56. PubMed ID: 23045285
[TBL] [Abstract][Full Text] [Related]
35. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
[TBL] [Abstract][Full Text] [Related]
36. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
37. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
38. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Kosaka T; Yamaki E; Mogi A; Kuwano H
J Biomed Biotechnol; 2011; 2011():165214. PubMed ID: 21687596
[TBL] [Abstract][Full Text] [Related]
40. [c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):464-9. PubMed ID: 24034993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]